The FDA has added a warning that GLP‑1 receptor agonists (used for diabetes, obesity, and more) are associated with a small but measurable increase in non‑arteritic anterior ischemic optic neuropathy (NAION), an optic‑nerve 'eye stroke' that can cause permanent vision loss. Large randomized trial meta‑analysis and real‑world sentinel surveillance show roughly a few extra NAION cases per 100,000 patients per year, so the absolute risk is low but clinically serious and important for informed prescribing and patient monitoring.
— Widespread use of GLP‑1 drugs means even rare, severe harms shape public‑health guidance, drug labeling, clinical consent, and debates over mass adoption of obesity medications.
Zayid Al-Aly
2026.11.20
100% relevant
U.S. Food and Drug Administration warning (Nov 9, 2026) based on pooled analysis of 126 randomized trials (134,253 patients) showing NAION rates 6.4 vs 3.8 per 100,000/year (≈2.6 excess cases/100k), and sentinel program data showing 32 vs 26 per 100,000/year (≈6 excess/100k) versus DPP‑4 inhibitors.
← Back to all ideas